Abstract
Here we highlight the Alzheimer’s Association’s role since its inception, as a strategic collaborator with National Institutes of Health–National Institute on Aging in the development of the modern era of the Alzheimer’s Movement and in making Alzheimer’s disease (AD) a national priority in the United States by developing several initiatives to advance knowledge about the cause, diagnosis, and treatment of dementia. Among these collaborative undertakings, the Alzheimer’s Disease Neuroimaging Initiative (ADNI) is an exemplary case, launched with groundwork by the Neuroimaging Working Group sponsored by the Association’s Ronald and Nancy Reagan Research Institute on AD. The unique contribution of the Association to the development of ADNI includes participation as a member of ADNI’s Private Partner Scientific Board and involvement in developing an AD biomarker standardization and validation subproject, which has led to a conceptual shift in the field to define AD based on its underlying biology. Furthermore, the creation of Worldwide ADNI (WW-ADNI) is highlighted, underscoring the global impact of these efforts.
Highlights
The Alzheimer’s Disease Neuroimaging Initiative (ADNI) is a keystone undertaking in the evolving landscape of Alzheimer’s disease (AD) research, and is now in its fourth iteration.
The Alzheimer’s Association has partnered with ADNI since its inception.
ADNI 4 and the Association continue to collaborate, ensuring representation within the study population.
If you do not see content above, kindly GO TO SOURCE.
Not all publishers encode content in a way that enables republishing at Neuro.vip.
This post is Copyright: Maria C. Carrillo,
Simin Mahinrad,
Heather M. Snyder,
Zaven Khachaturian | September 6, 2024